Clinical Trials
23 trialsNCT06756035 2026-06-04
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
Phase 1 Recruiting
NCT06915025 2026-06-02
OVATION-3
Imunon
Phase 3 Recruiting
NCT07341100 2026-06-01
Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT07617753 2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT06890338 2026-05-29
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT06819007 2026-05-26
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT07589543 2026-05-15
EB-DUALNK-OV
Beijing Biotech
Phase 1/2 Recruiting
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT07545460 2026-04-22
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT06994195 2026-04-20
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05397093 2026-04-15
ITIL-306 in Advanced Solid Tumors
Instil Bio
Phase 1 Terminated
NCT05238922 2026-04-14
Study of INCB123667 in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1 Recruiting
NCT04516447 2026-04-07
MUIR
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1 Recruiting
NCT05335993 2026-04-03
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT04498117 2026-04-01
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT06395519 2026-03-27
ERADIC8
858 Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07432633 2026-03-27
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Blue Earth Diagnostics
Phase 1/2 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting